Sam Brusco, Associate Editor12.02.22
Olympus has launched the moresolution power morcellator, which is manufactured by TROKAMED GmbH and available in the U.S. via a distribution agreement with Olympus America.
The moresolution morcellator is designed for advanced gynecologic procedures with large, calcified tissue specimens. Current FDA Guidance on power morcellator labeling requires all power morcellators marketed in the U.S. be used with a compatible, FDA-cleared containment device. The Olympus Contained Tissue Extraction System comprises the PneumoLiner containment device and moresolution, which provide select patients a laparoscopic option as an alternative to open hysterectomy or open myomectomy for tissue removal.
moresolution has the ability to cut dense or calcified fibroids, with efficient cutting to possibly help save time in the OR. The lightweight handpiece helps to reduce surgeon fatigue, and safety features include to option to keep the device in ‘Cut’ or ‘No Cut’ mode.
"We are excited to offer a new power morcellation solution for minimally invasive gynecological procedures," Richard Reynolds, president of the Medical System Group at Olympus America told the press. "Olympus supports the safe use of power morcellators with a contained extraction system according to FDA guidance. This device reflects a response to our customers' requests for more power and control during the procedure. This particular device works very well on very dense, calcified tissue, which is difficult to cut with other devices."
Contained tissue extraction isn’t indicated for women with a known or suspected malignancy. The FDA advises power morcellation shouldn’t be used to remove uterine tissue containing suspected fibroids in patients who are post-menopausal, over 50 years of age, or candidates for en bloc tissue removal vaginally or via a mini-laparotomy incision.
The moresolution morcellator is designed for advanced gynecologic procedures with large, calcified tissue specimens. Current FDA Guidance on power morcellator labeling requires all power morcellators marketed in the U.S. be used with a compatible, FDA-cleared containment device. The Olympus Contained Tissue Extraction System comprises the PneumoLiner containment device and moresolution, which provide select patients a laparoscopic option as an alternative to open hysterectomy or open myomectomy for tissue removal.
moresolution has the ability to cut dense or calcified fibroids, with efficient cutting to possibly help save time in the OR. The lightweight handpiece helps to reduce surgeon fatigue, and safety features include to option to keep the device in ‘Cut’ or ‘No Cut’ mode.
"We are excited to offer a new power morcellation solution for minimally invasive gynecological procedures," Richard Reynolds, president of the Medical System Group at Olympus America told the press. "Olympus supports the safe use of power morcellators with a contained extraction system according to FDA guidance. This device reflects a response to our customers' requests for more power and control during the procedure. This particular device works very well on very dense, calcified tissue, which is difficult to cut with other devices."
Contained tissue extraction isn’t indicated for women with a known or suspected malignancy. The FDA advises power morcellation shouldn’t be used to remove uterine tissue containing suspected fibroids in patients who are post-menopausal, over 50 years of age, or candidates for en bloc tissue removal vaginally or via a mini-laparotomy incision.